Drug interactions between Gemzar and Taxol
| Results for the following 2 drugs: |
|---|
| Gemzar (gemcitabine) |
| Taxol (paclitaxel) |
Interactions between your selected drugs
paclitaxel ↔ gemcitabine
Applies to:Taxol (paclitaxel) and Gemzar (gemcitabine)
MONITOR: Coadministration with paclitaxel may increase the plasma concentrations of gemcitabine, and high levels of gemcitabine may inhibit the intracellular accumulation of its active triphosphate metabolite. The mechanism of interaction has not been described. In one study, 14 patients with advanced non-small cell lung cancer received paclitaxel (110 mg/m2 over 3 hours) followed by gemcitabine (800 mg/m2 over 80 minutes) on days 1 and 8 every 21 days, with the exception of day 1 of cycle 1 when they received gemcitabine alone. Of 13 patients included in the pharmacokinetic analysis, 61% achieved the desired steady-state gemcitabine plasma concentration (10 to 20 microM) when the drug was administered alone, compared to 0% to 45% during cycles with paclitaxel. Paclitaxel significantly decreased systemic clearance and volume of distribution of gemcitabine, resulting in increased steady-state concentration. Gemcitabine pharmacokinetics demonstrated great interpatient variability when given alone, which was not observed during coadministration with paclitaxel.
MANAGEMENT: The potential for diminished pharmacologic effects of gemcitabine should be considered during coadministration with paclitaxel.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
